Arkansas

Psychedelic trials in Arkansas

15 registered trials has a study site in Arkansas, and 2 are recruiting now.

15

Trials with a site here

2

Recruiting

10

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30

Facilities

Where the research happens in Arkansas

Facility	City	Trials
Preferred Research Partners, Inc.	Little Rock	3
Preferred Research Partners	Little Rock	3
Pillar Clinical Research - Little Rock	Little Rock	1
Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR	Little Rock	1
Preferred Research Partners, Inc	Little Rock	1
Preferred Research Partners-NWA, LLC	Fayetteville	1
Clinical Site 126	Bentonville	1
Clinical Site 120	Little Rock	1
Clinical Site 129	Little Rock	1
University of Arkansas for Medical Sciences	Little Rock	1

Stay told

When a trial opens in Arkansas

All trials

Every trial with a Arkansas site

Trial	Status	Phase	Substance	Sites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLC	Completed	Phase 4	ketamine	54
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)NCT06809595 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	36
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	22
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona Institute	Active, not recruiting	Phase 3	psilocybin	29
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	90
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsNCT05407064 · Definium Therapeutics US, Inc.	Completed	Phase 2	lsd	22
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	46
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	13
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRDNCT05414422 · Perception Neuroscience	Completed	Phase 2	ketamine	21
The Effects of Sedatives on Tobacco Use DisorderNCT03813121 · Wake Forest University Health Sciences	Completed	Phase 1 / Phase 2	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere

Other states